Enterprise Value

6.944B

Cash

991M

Avg Qtr Burn

-85.58M

Short % of Float

8.78%

Insider Ownership

15.29%

Institutional Own.

86.54%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tavapadon Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Tavapadon (adjunct with L-Dopa) Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Phase 2

Data readout

Darigabat Details
Social Anxiety Disorder, Panic Disorder

Phase 2

Data readout

Emraclidine (CVL-231) Details
Brain disease, Schizophrenia

Phase 2

Data readout

Phase 2

Data readout

CVL-354 Details
Major depressive disorder

Phase 1

Data readout

Emraclidine (CVL-231) Details
Brain disease, Neurodegenerative disease, Alzheimer's disease

Phase 1

Data readout